memo-inOncology – SPECIAL ISSUE

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

Congress reports


Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.


ASCO 2020

memo – inOncology SPECIAL ISSUE

Congress Report virtual ASCO 2020

This report summarizes a selection of abstracts presented at ASCO 2020 in the areas of immunotherapy and targeted-therapy, some being explored either before or after surgery or in combination with radiation, for both non-small-cell and small-cell lung cancer.

Now available!

EHA 2020

memo – inHaematology SPECIAL ISSUE

Congress Report EHA 2020

This report summarizes a selection of abstracts presented at EHA 2020 in the areas of Waldenström’s macroglobulinemia, CLL, mantel cell lymphoma, B-cell-malignancies and potential treatment strategies for PNH and cold agglutinin disease.



All videointerviews from EHA 2020

Shirley D’Sa talks about promising new agents/regimens in the treatment of Waldenström’s macroglobulinemia with respect to efficacy and safety, next-generation BTK inhibitors and recent developments in the management of cold agglutinin disease.

Constantine Tam depicts the most interesting trial results in the field of CLL treatment at the EHA congress and gives an outlook on future treatment options for CLL and mantle cell lymphoma.

Veronique Leblond highlights relevant factors for the selection of treatment in newly diagnosed and relapsed Waldenström’s macroglobulinemia, the connection of BTK inhibitors and MYD88 or CXCR4 mutations and discusses the risk-benefit profile of these drugs.

Peter Hillmen gives an overview of the most relevant treatment strategies in ­patients with paroxysmal nocturnal hemoglobinuria and further explains the advantages of proximal over terminal complement inhibition.

All videointerviews from ASCO 2020

Victor Moreno provides insight into new investigational immune checkpoint inhibitors, safety profiles of combinational therapies and the importance of HLA B44 supertype in the context of lung cancer treatment. Moreover, he discusses the increased vulnerability of clinical research units during the COVID-19 crisis and their protection.

Helmut Prosch gives an overview on clinical and radiological response assessment of immunotherapy in lung cancer patients, specifically with regards to pneumonitis and atypical pulmonary findings.